These New Stem Cell Treatments Are Expensive — and Unproven
By Michael Hiltzik,
Los Angeles Times
| 08. 19. 2016
Untitled Document
Visitors to the website of StemGenex, a La Jolla medical group, could be forgiven for thinking that the answer to their prayers is finally at hand. Pitched at sufferers of lung disease, Parkinson’s, autoimmune conditions such as multiple sclerosis and rheumatoid arthritis and even Alzheimer’s, the site offers treatments based on injecting patients with stem cells drawn from their own body fat.
StemGenex has made “great strides in the advancement of stem cell therapy,” the site says, “and is dedicated to providing patients access to safe and effective stem cell treatments.” StemGenex backs up its medical claims with brief video testimonials from patients.
To the stem cell research establishment, pitches like StemGenex’s warrant caution. According to the International Society for Stem Cell Research, an organization of academic and clinical stem cell researchers, patients should be wary of “clinics that use persuasive language, including patient testimonials … to market their treatments”; of “expensive treatments that have not passed successfully through clinical trials” or are “offered without regulatory approval”; and of “clinics that offer the same cell treatment for a wide variety of...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
